Trial Profile
Effect of tolvaptan on RBF and GFR in ADPKD
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2018
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Polycystic kidney disease
- Focus Therapeutic Use
- 25 Jan 2018 Status changed from recruiting to discontinued.
- 13 Aug 2015 New trial record